IGM Biosciences Inc

IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The firm’s product pipeline includes IGM-2323, which is a CD20 x CD3 bispecific IgM antibody designed to treat patients with B cell Non-Hodgkin's lymphoma and other B cell malignancies, IGM-8444, which is an IgM antibody targeting Death Receptor 5 for the treatment of patients with solid and hematologic malignancies, and IGM-7354, which will target the delivery of IL-15 with the goal of inducing immune cell stimulation and proliferation. The company was founded in 2010 and is headquartered in Mountain View, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

IGM Biosciences reports progress in clinical development and strategic shifts

IGM Biosciences showcases progress in clinical development and financial performance.
Strategic shifts towards autoimmune indications present market opportunities.
Management addresses concerns and highlights safety profiles of key product candidates.
Potential for partnerships and differentiation in oncology and autoimmune diseases discussed.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

STOCKHOLM , March 31, 2023 /PRNewswire/ -- The shareholders of Medivir AB (publ), reg. no. 556238-4361, with its registered office in Huddinge, Stockholm, are hereby summoned to the annual general meeting on Thursday 4 May 2023 at 14.00 CEST at Tändstickspalatset, Västra Trädgårdsgatan 15, Stockholm, Sweden.

Notice of Annual General Meeting of Medivir AB (publ)

IGM Biosciences, Inc. (IGMS) delivered earnings and revenue surprises of 22.22% and 0.80%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

IGM Biosciences, Inc. (IGMS) Reports Q4 Loss, Misses Revenue Estimates

– Encouraging initial data from IGM-8444 combination with FOLFIRI; first patient dosed in randomized trial –

IGM Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

MOUNTAIN VIEW, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that it will report its fourth quarter and full year 2022 financial results on Thursday, March 30, 2023.

IGM Biosciences to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call and Webcast on March 30, 2023

STOCKHOLM , March 14, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that the first patient with hepatocellular carcinoma (HCC) has started treatment in phase 2a with the candidate drug fostroxacitabine bralpamide (fostrox) in combination with Lenvima®. In Medivir's ongoing phase 1b/2a study, fostrox is given in combination with two other drugs, either with Lenvima®, a tyrosine kinase inhibitor, or with Keytruda®, an anti-PD-1 checkpoint inhibitor.

First patient dosed in the phase 2a part of Medivir's study with fostrox in combination with Lenvima®

IGM Biosciences, Inc. is a leader in IgM antibody development. It stuck a major deal with Sanofi last year.

IGM Biosciences Looks Attractive Before Phase 2 Readout

STOCKHOLM , Feb. 23, 2023 /PRNewswire/ -- Medivir AB (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will present at the Erik Penser Bank Healthcare Day today, February 23, 2023. CEO Jens Lindberg will present the company and its plan for the ongoing clinical study with fostroxacitabine bralpamide (fostrox).

Medivir to present at the Erik Penser Bank Healthcare Day

STOCKHOLM , Feb. 21, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that the company's new Chief Medical Officer (CMO) Pia Baumann took up her position. As member of the company's management team her responsibilities include the continued clinical development of the candidate drug fostroxacitabine bralpamide (fostrox).

Pia Baumann takes up her position as Chief Medical Officer

MOUNTAIN VIEW, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Guggenheim 2023 Oncology Conference on Thursday, February 9, 2023, at 1:35 p.m. EST in New York.

IGM Biosciences to Present at the Guggenheim 2023 Oncology Conference

– Targeted IL-15/IL-15R IgM antibody to be evaluated for safety and pharmacodynamic effects – – Targeted IL-15/IL-15R IgM antibody to be evaluated for safety and pharmacodynamic effects –

IGM Biosciences Initiates First-in-Human Clinical Trial of IGM-7354 in Solid Tumors

MOUNTAIN VIEW, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 5:15 p.m. PST in San Francisco.

IGM Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

STOCKHOLM , Dec. 12, 2022 /PRNewswire/ -- Medivir AB (Nasdaq: MVIR) (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need,  announced today that the company has completed a pre-IND meeting with the US Food and Drug Administration and has received positive feedback on the development plan in preparation for an IND for its candidate drug fostroxacitabine bralpamide (fostrox). This is a significant step towards an application to include American study centers in future clinical trials (Investigational New Drug Application, IND).

Medivir has completed a successful pre-IND meeting with the FDA

First Preclinical Data for IGM-2644 and IGM-2537 Featured in Poster Presentations First Preclinical Data for IGM-2644 and IGM-2537 Featured in Poster Presentations

IGM Biosciences Presents Data from T cell Engager Portfolio for Hematologic Malignancies at 2022 American Society of Hematology Annual Meeting

MOUNTAIN VIEW, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a virtual fireside chat at the Bank of America Biotech SMID Cap Conference on Thursday, December 8, 2022 at 2:45 p.m. EST.

IGM Biosciences to Present at the Bank of America Biotech SMID Cap Conference

IGM Biosciences, Inc. (IGMS) delivered earnings and revenue surprises of 8.97% and 15.13%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

IGM Biosciences, Inc. (IGMS) Reports Q3 Loss, Lags Revenue Estimates

– Data from T cell Engager Portfolio for Hematologic Malignancies, Including First Preclinical Data for IGM-2644 and IGM-2537, Selected for Poster Presentations at 2022 ASH Annual Meeting –

IGM Biosciences Announces Third Quarter 2022 Financial Results and Provides Corporate Update

ADC Therapeutics

IGM Biosciences and ADC Therapeutics Announce Clinical Collaboration Agreement to Evaluate Imvotamab (IGM-2323) in Combination with ZYNLONTA® in Patients with Relapsed or Refractory B Cell Non-Hodgkin's Lymphoma

STOCKHOLM , Sept. 12, 2022  /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, today announces that the company will present at the H.C.

Medivir to present at the H.C. Wainwright 24th Annual Global Investment Conference

STOCKHOLM , Sept. 8, 2022 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, today announces that an abstract about its lead program fostroxacitabine bralpamide (fostrox) and the potential efficacy in primary liver cancer has been accepted for presentation at the SITC 37th Annual Meeting, held November 10-12, 2022, in Boston, USA.

Medivir to present data on additive efficacy of fostrox in combination with anti-PD1 in nonclinical tumor models at the SITC 2022 Annual Meeting

– Continued Advancement in Clinical Development of Imvotamab (IGM-2323) and IGM-8444 –

IGM Biosciences Announces Second Quarter 2022 Financial Results and Provides Corporate Update

MOUNTAIN VIEW, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the 2022 Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 3:00 p.m. EST in New York.

IGM Biosciences to Present at the 2022 Jefferies Healthcare Conference

MOUNTAIN VIEW, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the 2022 RBC Capital Markets Global Healthcare Conference on Tuesday, May 17, 2022 at 9:30 a.m. EST in New York.

IGM Biosciences to Present at the 2022 RBC Capital Markets Global Healthcare Conference

–   Closing of Global Collaboration Agreement with Sanofi; $150 Million Upfront Payment to IGM –

IGM Biosciences Announces First Quarter 2022 Financial Results and Provides Corporate Update

$150 Million Payment to IGM from Sanofi $150 Million Payment to IGM from Sanofi

IGM Biosciences Announces Closing of Global Collaboration Agreement with Sanofi

HUDDINGE, Sweden, May 5, 2022 /PRNewswire/ -- Medivir Aktiebolag (publ) held its annual shareholders' meeting today on 5 May 2022. The annual general meeting was held by physical presence of shareholders and with the option for shareholders to exercise their voting rights by advance voting (postal voting).

News for IGM Biosciences Inc Stock (IGMS)